Does the media prefer FDMT or CRDL?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.28 beat Cardiol Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NGNE or CRDL more profitable?

Neurogene's return on equity of -37.88% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Cardiol Therapeutics N/A -229.43% -165.60%

Does the media prefer NGNE or CRDL?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, IMMX or CRDL?

Immix Biopharma is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is IMMX or CRDL more profitable?

Immix Biopharma's return on equity of -73.24% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Cardiol Therapeutics N/A -229.43% -165.60%

Does the media prefer IMMX or CRDL?

In the previous week, Immix Biopharma had 11 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 14 mentions for Immix Biopharma and 3 mentions for Cardiol Therapeutics. Immix Biopharma's average media sentiment score of 1.26 beat Cardiol Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CRDL or AVTE?

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 705.69%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CRDL or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is CRDL or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Aerovate Therapeutics N/A -90.19% -77.47%

Is CRDL or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Contineum Therapeutics N/A -27.09% -25.64%

Does the media favor CRDL or CTNM?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 1 mentions for Contineum Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Contineum Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardiol Therapeutics (CRDL) Competitors

$1.06 +0.03 (+2.43%)

As of 02:36 PM Eastern

Compare

CRDL vs. FDMT, NGNE, IMMX, AVTE, and CTNM

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include 4D Molecular Therapeutics (FDMT), Neurogene (NGNE), Immix Biopharma (IMMX), Aerovate Therapeutics (AVTE), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.28 beat Cardiol Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Cardiol Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.06	-$140.11M	-$2.57	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Cardiol Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

4D Molecular Therapeutics presently has a consensus price target of $29.88, suggesting a potential upside of 159.62%. Cardiol Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 705.69%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

4D Molecular Therapeutics beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Cardiol Therapeutics has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	520.81	-$90.35M	-$4.55	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Neurogene currently has a consensus price target of $84.83, indicating a potential upside of 176.74%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 705.69%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Neurogene's return on equity of -37.88% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Neurogene has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neurogene beats Cardiol Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Immix Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Immix Biopharma's return on equity of -73.24% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immix Biopharma is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Immix Biopharma presently has a consensus target price of $20.67, indicating a potential upside of 114.16%. Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 705.69%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Immix Biopharma had 11 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 14 mentions for Immix Biopharma and 3 mentions for Cardiol Therapeutics. Immix Biopharma's average media sentiment score of 1.26 beat Cardiol Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immix Biopharma beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Aerovate Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 0 mentions for Aerovate Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Aerovate Therapeutics	Neutral

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 705.69%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics' return on equity of -90.19% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Cardiol Therapeutics beats Aerovate Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Contineum Therapeutics' return on equity of -27.09% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 1 mentions for Contineum Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Contineum Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 705.69%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 50.66%. Given Cardiol Therapeutics' higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cardiol Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Contineum Therapeutics	$50M	9.93	-$59.98M	-$1.95	N/A

Summary

Contineum Therapeutics beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$121.59M	$3.01B	$6.66B	$12.19B
Dividend Yield	N/A	1.78%	2.68%	5.89%
P/E Ratio	-3.77	18.83	25.35	24.07
Price / Sales	N/A	703.13	588.85	125.28
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	9.59	4.13	10.56	6.37
Net Income	-$24.20M	$64.45M	$3.56B	$337.11M
7 Day Performance	-0.47%	0.55%	1.00%	-0.93%
1 Month Performance	-20.08%	0.26%	0.80%	0.65%
1 Year Performance	-27.24%	24.90%	31.01%	29.50%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	1.7936 of 5 stars	$1.06 +2.4%	$8.50 +705.7%	-23.1%	$121.59M	N/A	N/A	20	News Coverage Positive News
FDMT 4D Molecular Therapeutics	1.8663 of 5 stars	$9.22 +4.4%	$29.88 +224.0%	+190.5%	$461.60M	$85.21M	N/A	120	News Coverage Insider Trade
NGNE Neurogene	2.6006 of 5 stars	$29.86 +2.6%	$79.86 +167.4%	+74.8%	$459.83M	$930K	N/A	90	News Coverage
IMMX Immix Biopharma	3.7172 of 5 stars	$8.47 +0.2%	$19.50 +130.2%	+348.0%	$459.78M	N/A	N/A	9	News Coverage
AVTE Aerovate Therapeutics	N/A	$15.34 -4.6%	N/A	+122.6%	$444.63M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. FDMT, NGNE, IMMX, AVTE, and CTNM

How does Cardiol Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does Cardiol Therapeutics compare to Neurogene?

Summary

How does Cardiol Therapeutics compare to Immix Biopharma?

Summary

How does Cardiol Therapeutics compare to Aerovate Therapeutics?

Summary

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. FDMT, NGNE, IMMX, AVTE, and CTNM

How does Cardiol Therapeutics compare to 4D Molecular Therapeutics?

Does the media prefer FDMT or CRDL?

Which has more risk and volatility, FDMT or CRDL?

Which has higher earnings and valuation, FDMT or CRDL?

Is FDMT or CRDL more profitable?

Do institutionals and insiders have more ownership in FDMT or CRDL?

Do analysts recommend FDMT or CRDL?

Summary

How does Cardiol Therapeutics compare to Neurogene?

Which has stronger earnings and valuation, NGNE or CRDL?

Do analysts recommend NGNE or CRDL?

Is NGNE or CRDL more profitable?

Which has more risk & volatility, NGNE or CRDL?

Do institutionals & insiders believe in NGNE or CRDL?

Does the media prefer NGNE or CRDL?

Summary

How does Cardiol Therapeutics compare to Immix Biopharma?

Which has more volatility & risk, IMMX or CRDL?

Is IMMX or CRDL more profitable?

Do institutionals and insiders believe in IMMX or CRDL?

Which has better valuation and earnings, IMMX or CRDL?

Do analysts recommend IMMX or CRDL?

Does the media prefer IMMX or CRDL?

Summary

How does Cardiol Therapeutics compare to Aerovate Therapeutics?

Does the media favor CRDL or AVTE?

Do insiders and institutionals believe in CRDL or AVTE?

Do analysts rate CRDL or AVTE?

Is CRDL or AVTE more profitable?

Which has more risk & volatility, CRDL or AVTE?

Which has preferable valuation and earnings, CRDL or AVTE?

Summary

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Is CRDL or CTNM more profitable?

Which has more risk & volatility, CRDL or CTNM?

Do insiders & institutionals believe in CRDL or CTNM?

Does the media favor CRDL or CTNM?

Do analysts recommend CRDL or CTNM?

Which has preferable earnings and valuation, CRDL or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools